10-K: CareDx Reports 14% Revenue Growth in 2025, Navigates Legal & Reimbursement Shifts

CareDx, a precision medicine company, reported a 14% increase in total revenue to $379.8 million for fiscal year 2025, alongside a net loss of $21.4 million, while successfully remediating a material weakness in internal controls and settling a securities class action.

Summary

• Total revenue for the year ended December 31, 2025, increased by 14% to $379.8 million, up from $333.8 million in 2024.
• Testing services revenue grew by 10% to $274.5 million, driven by a 14% increase in testing volume to approximately 200,000 commercial tests.
• Product revenue increased by 19% to $48.4 million, primarily due to higher sales of NGS-based kitted solutions.
• Patient and digital solutions revenue rose by 31% to $56.9 million, attributed to higher pharmacy sales and an expanded customer base for Ottr software.
• The company reported a net loss of $21.4 million for 2025, a significant shift from a net income of $52.5 million in 2024.
• Cash flow from operations increased to $42.0 million in 2025 from $38.0 million in 2024.
• CareDx repurchased 5.8 million shares of common stock for $87.8 million under its February 2025 and May 2025 Repurchase Programs.
• The U.S. District Court for the Eastern District of Texas vacated the FDA's 2024 final rule for greater oversight of Laboratory Developed Tests (LDTs) in April 2025, and the FDA reverted its policy in September 2025, limiting its authority over CareDx's testing services.
• A material weakness in internal control over financial reporting as of December 31, 2024, was successfully remediated during 2025.
• The company settled a federal securities class action lawsuit for approximately $20.25 million, with final court approval and payment occurring in December 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing with mixed sentiment. While revenue growth across all segments and the remediation of internal control weaknesses are positive, the shift from net income to a net loss and ongoing uncertainties in Medicare reimbursement and legal appeals present significant challenges. The strategic focus on 'TRANSPLANT+' and R&D pipeline offers future potential, but current financial performance and regulatory risks temper enthusiasm.

Positives

• Total revenue increased by 14% year-over-year to $379.8 million in 2025.
• Testing services volume grew by approximately 14% to 200,000 commercial tests in 2025.
• Product revenue increased by 19% and patient and digital solutions revenue increased by 31% in 2025.
• Cash flow from operations improved to $42.0 million in 2025 from $38.0 million in 2024.
• The SEC concluded its investigation into the company in September 2023, with no enforcement action recommended.
• The DOJ declined to intervene in a qui tam action in October 2024, closing its investigation with no finding of wrongdoing against the company.
• The U.S. District Court overturned a jury verdict against CareDx in the Natera patent infringement case on February 24, 2025, concluding Natera's patents 11,111,544 and 10,655,180 were invalid.
• The material weakness in internal control over financial reporting identified as of December 31, 2024, was successfully remediated during 2025.
• HeartCare expanded its indication to cover pediatric patients of all ages starting at birth in 2025.
• A 2025 study published in the American Journal of Transplantation demonstrated AlloSure is a clinically actionable tool for kidney transplant surveillance, strongly predicting rejection, improving biopsy yield, and enabling earlier intervention.

Negatives

• The company incurred a net loss of $21.4 million in 2025, compared to a net income of $52.5 million in 2024.
• Revenue from Medicare for testing services decreased to 46% of total testing services revenue in 2025, down from 50% in 2024 and 53% in 2023.
• The Medicare reimbursement rate for AlloSure Kidney decreased by $88 to $2,753, effective January 1, 2026.
• A new Proposed Draft foundational LCD (DL40058, DL40060) for Solid Organ Allograft Rejection testing, released July 17, 2025, could introduce new coverage criteria and utilization limitations, potentially leading to fewer surveillance tests being reimbursed.
• The company's accumulated deficit increased to $735.4 million as of December 31, 2025.
• Cash, cash equivalents, and marketable securities decreased to $201.4 million as of December 31, 2025, from $260.7 million at December 31, 2024.

Risks

• History of losses and expectation to incur net losses for the next several years.
• Substantial portion of revenues from Medicare, and risk of loss or significant reduction in reimbursement from Medicare.
• Financial results largely dependent on sales of AlloSure Kidney, AlloMap Heart, AlloSure Heart, HeartCare, and AlloSure Lung tests and products.
• Exposure to legal proceedings that could be time-consuming, costly, and divert management attention.
• Development and commercialization of additional diagnostic solutions is a lengthy and complex process with no guarantee of success.
• The field of diagnostic testing in transplantation is evolving and subject to rapid technological change, potentially rendering current solutions outdated.
• Clinicians, hospital administrators, medical centers, and laboratories may not adopt diagnostic solutions due to historical practices or more favorable reimbursement policies for other monitoring means.
• Quarterly operating results may fluctuate significantly or fall below expectations, causing stock price volatility.
• Inability to maintain existing clinical collaborations and enter into new ones could delay product commercialization and development.
• Inability to successfully manage growth and support demand for tests could harm the business.
• Past revenue growth rates may not be indicative of future growth, and revenue may decline.
• If the laboratory facility in the U.S. becomes inoperable, the company will be unable to perform testing services.
• Investor expectations regarding environmental, social, and governance (ESG) factors may impose additional costs and risks.
• Performance issues, service interruptions, or price increases by shipping carriers could adversely affect the business.
• Inability to raise additional capital on acceptable terms in the future may limit development and commercialization efforts.
• Loss of key members of senior management team or inability to attract and retain highly skilled personnel could adversely affect the business.
• Undetected errors or defects in products could result in corrective actions, harm reputation, decrease market acceptance, and expose the company to liability.
• Extensive reliance on third-party service providers, with failure to perform potentially interfering with ability to provide test results and kits.
• Security breaches, loss of data, or other disruptions could compromise sensitive information, prevent access to critical information, and expose the company to liability.
• Subject to changing laws, regulations, standards, and contractual obligations related to privacy, data protection, and data security.
• International expansion exposes the company to business, regulatory, political, operational, financial, and economic risks.
• Incorporation of AI technologies may present business, compliance, and reputational risks.
• Disputes with labor unions may adversely affect ability to operate in the Sweden facility.
• Operating results may be adversely affected by unfavorable economic and market conditions.
• Effective tax rate may fluctuate, and obligations in tax jurisdictions may exceed accruals.
• Use of hazardous materials in a manner that causes injury could lead to liability for damages.
• Changes in accounting rules and regulations could result in unfavorable accounting changes.
• Intangibles, including goodwill, acquired in connection with acquisitions may subsequently be impaired.
• Recent and future acquisitions and investments could disrupt business, harm financial condition, dilute ownership, and increase debt.
• License and Commercialization Agreement with Illumina may not result in material benefits.
• Billing complexities associated with obtaining payment or reimbursement for current and future solutions may negatively affect revenue, cash flows, and profitability.
• Healthcare reform measures could hinder or prevent the commercial success of products.
• Compliance with CLIA and federal and state laws and regulations governing clinical laboratories and LDTs, including FDA regulations.
• Subject to numerous fraud and abuse and other laws and regulations, violation of which could harm the business.
• Competitive position depends on maintaining intellectual property protection.
• Dependence on licenses from third parties.
• Techniques employed by short sellers may drive down the market price of common stock.
• No expectation to pay dividends in the foreseeable future, requiring reliance on stock appreciation for return.
• Stock repurchase programs might limit ability to pursue other growth opportunities.
• Inability to substantially utilize net operating loss carryforwards could harm financial results.
• Organizational documents and Delaware law make a takeover more difficult.
• Designation of federal district courts as exclusive forum for Securities Act claims could limit stockholders' ability to obtain a favorable judicial forum.

Future Outlook

CareDx plans to accelerate profitable growth by focusing on solutions-selling at transplant centers, integrating digital and patient solutions with laboratory products, generating clinical evidence for optimal payer coverage and reimbursement, and executing on its R&D pipeline to address unmet medical needs. The company aims to expand its total addressable market through the 'TRANSPLANT+' initiative, exploring adjacencies like preand peri-transplant organ assessment and precursor disease areas. Operational excellence will be driven by process improvement and strategic investments in enterprise applications, AI, and business intelligence tools.

Management Comments

• We aim to create life-changing solutions that enable transplant patients to thrive.
• We believe solutions selling into the same transplant center increases the adoption and adherence to our diagnostic products and allows us to lower our revenue acquisition costs over time.
• We expect our digital business will drive the next wave of innovation for the company by enabling us to build new products and solutions to help transplant centers operate more efficiently, do more transplants, and grow profitably.
• We believe that this combination remaining focused on a concentrated number of transplant centers, lowering our cost of revenue acquisition by cross-selling more solutions into the same institutions, and gaining leverage on our commercial channel forms a clear and differentiated formula for profitable growth in the molecular diagnostics market.
• We recognize that our people are the driving force behind our success, and we cannot unlock our full growth potential without engaging and inspiring the employees that deliver value to our patients and customers.

Industry Context

StockSavvy.ai notes that CareDx operates in a highly competitive and rapidly evolving molecular diagnostics market for transplantation. The company differentiates itself by focusing on a concentrated market of transplant centers with a portfolio of integrated solutions, aiming to increase adoption and lower customer acquisition costs through cross-selling. The industry is characterized by rapid technological development, with competitors like Natera and Eurofins also offering molecular diagnostic tests. Regulatory changes, particularly concerning Laboratory Developed Tests (LDTs) and Medicare reimbursement policies, significantly impact market dynamics and commercial success. The recent vacating of the FDA's LDT oversight rule and subsequent policy reversion provide temporary relief but highlight ongoing regulatory uncertainty. The increasing focus on AI in healthcare also presents both opportunities for innovation and new compliance risks for companies in this sector.

Comparison to Industry Standards

• The filing mentions Natera, Inc., Eurofins Transplant Genomics, Inc., Devyser Diagnostics AB, and Insight Molecular Diagnostics, Inc. (iMDx) as competitors in post-transplant surveillance molecular diagnostics.
• Thermo Fisher (One Lambda business), Omixon, GenDx, BAG, Qiagen, and Immucor are cited as competitors in HLA tissue typing markets.
• Phoenix (Epic's transplant application) and T-REX/MedSleuth are noted as competitors in digital patient management and referral applications.
• The company believes it competes favorably on factors such as quality of clinical data, confidence in diagnostic results, technical performance, reputation, reimbursement extent, inclusion in practice guidelines, cost-effectiveness, and ease of use.
• No specific global benchmarks or direct comparisons of CareDx's financial performance or product efficacy against these named competitors' specific results are provided in the filing to assess industry standards.

Management Changes

Corporate Governance

Legal Proceedings

• **Natera Patent Infringement and False Advertising**: The U.S. District Court for the District of Delaware overturned a jury verdict on February 24, 2025, concluding Natera's U.S. Patents 11,111,544 and 10,655,180 were invalid for lack of written description, thereby reversing a $96.3 million damages award against CareDx. Natera has appealed this decision. Separately, in a false advertising case, the U.S. Court of Appeals for the Third Circuit affirmed the District Court's findings on liability and damages on August 28, 2025, but CareDx filed a petition for Supreme Court review on February 9, 2026, regarding the damages decision.
• **United States Department of Justice (DOJ) and Securities and Exchange Commission (SEC) Investigations**: The SEC concluded its investigation into the company in September 2023, with no enforcement action intended. The DOJ declined to intervene in a qui tam action in October 2024, closing its investigation with no finding of wrongdoing. However, the private plaintiff (Relator) in the qui tam action filed an amended complaint on April 8, 2025, which CareDx intends to vigorously defend against.
• **Securities Class Action**: The company reached an agreement-in-principle to resolve a federal securities class action for approximately $20.25 million on April 22, 2025. The District Court granted final approval of the settlement on December 4, 2025, and the company paid the settlement amount.
• **Derivative Actions (Edelman v. Bickerstaff and Burns Derivative Action)**: Two stockholder derivative actions were filed, alleging breaches of fiduciary duty and other claims. The parties reached an agreement in principle to resolve these cases on July 22, 2025, subject to attorney fee negotiation. Preliminary court approval of the settlement was granted on December 9, 2025, subject to resolution of attorney's fees.

Stakeholder Impact

• **Shareholders**: Impacted by the net loss, stock repurchase programs, and the volatility of the common stock price due to various factors including legal outcomes and market conditions. The shelf registration statement could lead to future dilution if equity securities are issued.
• **Employees**: Affected by the company's focus on performance culture, training opportunities, and competitive compensation. The SSP production group in Sweden is represented by a collective bargaining agreement, introducing labor relations considerations.
• **Patients**: Benefit from the company's precision medicine solutions aimed at improving transplant outcomes, including non-invasive molecular testing and digital health technologies. Access to these tests is influenced by reimbursement policies.
• **Clinicians/Healthcare Providers**: Provided with diagnostic tools and digital solutions to improve patient management and outcomes. Adoption of new tests depends on clinical evidence, ease of use, and reimbursement.
• **Payers (Medicare, Private Insurers)**: Directly impacted by reimbursement rates and coverage policies for the company's diagnostic tests. Changes in these policies, such as the proposed LCD revisions, can significantly affect the company's revenue and profitability.

Next Steps

• MolDX and Noridian intend to issue a new LCD for solid organ allograft rejection testing in the coming months.
• The company will continue dialogue with CMS regarding the interpretation of LCDs for Medicare reimbursement.
• The company intends to defend itself vigorously in the ongoing Natera patent invalidation appeal.
• The company intends to vigorously defend itself against the amended complaint in the qui tam action.
• The motion for preliminary approval of the derivative settlement remains under consideration, with a scheduled oral argument for December 2, 2025.
• The company will continue to invest in research and development to develop additional services and products.
• The company will continue to scale its organization efficiently and make strategic investments in enterprise applications, remote process automation, artificial intelligence, and business intelligence tools.
• The company will continue to attract, develop, and retain employees with the experience, knowledge, expertise, and vision capable of excelling in the complex and competitive business environment.

Key Dates

Recommendation

CareDx's 2025 results present a mixed picture, warranting a 'hold' recommendation. While the company demonstrated strong revenue growth across all segments and successfully remediated a material weakness in internal controls, the shift from a net income in 2024 to a net loss in 2025 is a significant concern. The legal landscape, particularly the favorable overturning of the Natera patent infringement verdict, is a positive, but ongoing appeals and the qui tam action introduce continued uncertainty. Potential changes in Medicare reimbursement policies, including the proposed LCD, pose a material risk to future revenue. The company's strategic initiatives for growth and market expansion are promising, but their impact on profitability remains to be seen. Investors should monitor the outcomes of legal appeals, future reimbursement decisions, and the execution of the 'TRANSPLANT+' strategy before making further investment decisions.

Keywords

Precision Medicine, Transplant Diagnostics, Molecular Testing, Organ Health, AlloSure Kidney, AlloMap Heart, AlloSure Heart, HeartCare, AlloSure Lung, dd-cfDNA, Gene Expression Profiling, Digital Health, Patient Solutions, Laboratory Products, SEC Filing, 10-K, Financial Results, Reimbursement, Clinical Trials, Intellectual Property, Corporate Governance, Risk Management, Biopharma Partnerships, Transplant Centers, Genomics, AI in Healthcare, Cybersecurity